IDH1 and central nervous system cancer: However, a phase II study did not show a benefit of the PARP inhibitor veliparib in patients with non IDH mutated glioblastoma given in addition to temozolomide [49], but trial results of ongoing studies for IDH mutant glioma are pending [50].